SABS — SAB Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1833214 ·
Last close
$3.81
Market Cap
$291.33M
52W High
$5.15
52W Low
$3.40
ADV30
881,814
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,997,736 | -18,868,885 | 248,470,498 | 20,519,724 | 21,222,197 |
| Dec 2025 | 0 | — | -15,770,231 | -16,860,743 | 172,809,969 | 10,502,680 | 21,315,594 |
| Sep 2025 | 0 | — | -12,678,969 | 45,445,469 | 183,448,368 | 29,424,708 | 18,374,019 |
| Jun 2025 | 0 | — | -9,732,061 | -10,114,270 | 30,129,488 | 3,692,217 | 18,113,273 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-44,775,111
Investing CF
$-121,706,130
Financing CF
$168,299,452
CapEx
$-155,677
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.98
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-110,895,167
Inventory
—
Receivables
$946,781
ST Investments
$86,089,779
EBIT TTM
$13,514,347
Pretax Income TTM
$13,273,683
Interest Exp TTM
$240,664
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,953,363 | 13,273,683 | 172,809,969 | 21,315,594 | — | -44,775,111 |
| Dec 2024 | 0 | -42,910,520 | -34,105,309 | 44,195,469 | 18,225,893 | — | -34,292,009 |
| Dec 2023 | 0 | -38,075,320 | -42,193,786 | 83,941,253 | 26,641,812 | — | -25,119,405 |
| Dec 2022 | 0 | -28,917,617 | -18,740,804 | 50,904,927 | 19,846,785 | — | -23,459,511 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc. | $299.93M | $8.17 | — |
| EDIT | Editas Medicine, Inc. | $301.55M | $3.08 | — |
| SRZN | Surrozen, Inc./DE | $303.84M | $26.17 | — |
| VACH | Voyager Acquisition Corp./Cayman Islands | $270.96M | $10.71 | — |
| TARA | Protara Therapeutics, Inc. | $269.78M | $4.80 | — |
News headlines (Yahoo Finance, 1h cache)
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
2026-05-20 20:43 · Yahoo
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
2026-05-15 11:32 · Yahoo
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
2026-05-12 23:03 · Yahoo
SAB Biotherapeutics Q1 Earnings Call Highlights
2026-05-12 17:14 · Yahoo
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
2026-05-12 11:30 · Yahoo
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
2026-05-05 12:30 · Yahoo
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
2026-04-29 11:35 · Yahoo
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
2026-04-22 11:00 · Yahoo
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
2026-04-15 12:00 · Yahoo
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-03-19 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.